Phase I Study of Folate Conjugate EC145 (Vintafolide) in Patients With Refractory Solid Tumors

PURPOSE: EC145 (vintafolide), a conjugate of folic acid and the vinca alkaloid desacetylvinblastine hydrazide (DAVLBH), is a ligand for the folate receptor (FR), with activity against FR-positive tumor xenografts in vivo. This phase I study determined the maximum-tolerated dose (MTD) of EC145 admini...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: LoRusso, Patricia M., Edelman, Martin J., Bever, Susan L., Forman, Karen M., Pilat, MaryJo, Quinn, Mary F., Li, Jing, Heath, Elisabeth I., Malburg, Lisa M., Klein, Patrick J., Leamon, Christopher P., Messmann, Richard A., Sausville, Edward A.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Clinical Oncology 2012
Soggetti:
ORIGINAL REPORTS
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4104289/
https://ncbi.nlm.nih.gov/pubmed/23032618
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2011.41.4946
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi